ICI: Performance, Capabilities, Goals and Strategies in the Worldwide Chemical Market
US$ 1,560.00
... competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company's performance, capabilities, goals, and strategies in the global chemical market. Contains 55 pages and 12 tables
December 2010
55 pages
The 2011 Leading Food and Beverage Companies Financial Analyses
US$ 1,480.00
Global PDF: US$ 3,900.00 Each company analysis provides: The U.S. and international food and beverage sales and operating profit by geographic region, market segment, division and product line. Five-year food and beverage sales and operating profit performance. The companies analyzed in the ...
October 2010
100 pages
The 2011 Top Ten World's Leading Life Science Intermediates Companies
US$ 10,000.00
... include: To establish a comprehensive, factual and cost-effective information base on performance, capabilities, goals and strategies of the world’s leading life science intermediates companies. To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a- ...
October 2010
600 pages
The 2011Global Life Science Intermediates Market Dynamics and Trends
US$ 1,480.00
... PDF: US$ 3,900.00 A concise market analysis, including: Major U.S. and international trends with potentially significant impact on the life science intermediates industry during the next five years, including industry consolidation, market globalization, environmental regulations, etc. Analysis of major ...
October 2010
29 pages
The 2011 Leading Life Science Intermediates Companies Marketing Tactics
US$ 1,480.00
Global PDF: US$ 3,900.00 For each company, the analysis presents: Major promotional strategies. Distribution approaches. Product service and support. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia. Contains 20 pages
October 2010
20 pages
The 2011 Leading Life Science Intermediates Companies Comparative Analysis
US$ 680.00
Global PDF: US$ 1,900.00 This report ranks the world’s major life science intermediates companies according to the following criteria: Estimated sales in Europe, North America, Asia, and other geographic regions. Operating profit. R&D expenditures. The companies analyzed in the report: BASF, Bayer/ ...
October 2010
5 pages
The 2011 Leading Life Science Intermediates Companies Collaborations
US$ 1,480.00
Global PDF: US$ 3,900.00 For each company, the report presents: Major joint venture, distribution, OEM and licensing partners, both industrial and academic. Terms of collaborative agreements and specific products involved. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, ...
October 2010
70 pages
The 2011 Leading Life Science Intermediates Companies Financial Analyses
US$ 1,480.00
Global PDF: US$ 3,900.00 Each company’s analysis provides: Sales and operating profit by division, product line, geographic region and country. Five-year sales and profit performance. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep ...
October 2010
105 pages
The 2011 Leading Life Science Intermediates Companies Organizations and Management
US$ 1,480.00
Global PDF: US$ 3,900.00 For each company, the report provides: History of the life science intermediates business evolution, important to the understanding of the corporate culture, management mentality and strategies. Recent acquisitions, divestitures and significant organizational changes. Current ...
October 2010
110 pages
The 2011 Leading Life Science Intermediates Companies R&D Expenditures and Major Programs
US$ 1,480.00
Global PDF: US$ 3,900.00 For each company, the report provides: Estimated R&D budget. Research facilities and staff. New technologies, products and applications in development. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and ...
October 2010
32 pages
The 2011 Leading Life Science Intermediates Companies Product Portfolio Analyses
US$ 1,480.00
Global PDF: US$ 3,900.00 For each company, the analyses present: Extensive review of the major product lines. New product introductions and line extensions. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia. Contains 57 ...
October 2010
57 pages
The 2011 Top Ten World’s Leading Pharmaceutical Companies
US$ 10,560.00
... To establish a comprehensive, factual, annually-updated and cost-effective information base on performance, capabilities, goals and strategies of the world’s leading pharmaceutical companies. To help current suppliers realistically assess their financial, marketing and technological capabilities vis-a-vis ...
October 2010
1200 pages
The 2011 Leading Pharmaceutical Companies Strategic Directions
US$ 1,480.00
... product development, and marketing objectives and strategies. Anticipated acquisitions, joint ventures and divestitures. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - ...
October 2010
45 pages
The 2011 Leading Pharmaceutical Companies Financial Analyses
US$ 1,480.00
... , geographic region, therapeutic category, and individual drug. Five-year sales and operating profit performance. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - Novartis ...
October 2010
130 pages
The 2011 Leading Pharmaceutical Companies Collaborative Arrangements
US$ 1,480.00
... , and licensing partners, both industrial and academic. Terms of collaborative agreements and specific products involved. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - ...
October 2010
200 pages
The 2011 Leading Pharmaceutical Companies Technological Know-How
US$ 1,480.00
... capabilities. Know-how in biotechnology and other pertinent fields. Proprietary technologies and patent litigations. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - ...
October 2010
50 pages
The 2011 Leading Pharmaceutical Companies Product Portfolio Analyses
US$ 1,480.00
... review of major ethical, OTC, and generic drugs. Most recent new drug introductions and indications. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - Novartis - ...
October 2010
275 pages
The 2011 Leading Pharmaceutical Companies Marketing Tactics
US$ 1,480.00
... force in the U.S., Europe, Asia, and other geographic regions. Distribution strategies. Major promotional tactics. The companies analyzed in the report: - AstraZeneca - Bristol-Myers Squibb - GlaxoSmithKline - Johnson & Johnson - Merck - Novartis ...
October 2010
60 pages
The 2011 Leading Pharmaceutical Companies Comparative Analysis
US$ 680.00
Global PDF: US$ 1,900.00 This report ranks the world’s major pharmaceutical companies according to the following criteria: Sales and market shares. Operating profit and margins. R&D expenditures and percent of sales. The companies analyzed in the report: - AstraZeneca - Bristol- ...
October 2010
